In vivo drug resistance mutation dynamics from the early to chronic stage of infection in antiretroviral-therapy-naïve HIV-infected men who have sex with men.
Cintia CevallosAndrés C A CulassoJavier UrquizaDiego OjedaOmar SuedMaría I FigueroaMaría M AvilaM Victoria DelpinoJorge Fabián QuarleriPublished in: Archives of virology (2020)
Human immunodeficiency virus type 1 (HIV) primary drug resistance mutations (DRMs) influence the long-term therapeutic effects of antiretroviral treatment (ART). Drug-resistance genotyping based on polymerase gene sequences obtained by next-generation sequencing (NGS) was performed using samples from 10 ART-naïve HIV-infected men who have sex with men (MSM; P1-P10) from the acute/early to chronic stage of infection. Three of the 10 subjects exhibited the presence of major (abundance, ≥ 20%) viral populations carrying DRM at early/acute stage that later, at the chronic stage, dropped drastically (V106M) or remained highly abundant (E138A). Four individuals exhibited additional DRMs (M46I/L; I47A; I54M, L100V) as HIV minority populations (abundance, 2-20%) that emerged during the chronic stage but ephemerally.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- men who have sex with men
- hiv testing
- hiv infected patients
- hiv aids
- liver failure
- drug induced
- genetic diversity
- acute respiratory distress syndrome
- high throughput
- south africa
- sars cov
- microbial community
- hepatitis c virus
- copy number
- intensive care unit